• Generex Biotechnology Corp., of Toronto, reported that in a Phase III trial carried out by Shreya Life Sciences Pvt. Ltd., Oral-lyn buccal insulin spray significantly lowered HbA1c at six weeks and 12 weeks compared to baseline. Injected regular insulin did not significantly lower HbA2c until 12 weeks. Adverse events were tolerable between groups and Oral-lyn was found to be well tolerated. Shreya submitted a dossier in December 2012 to regulatory authorities in India.

• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., published results from two Phase I trials of Pennvax-B vaccine for HIV delivered with a DNA adjuvant and with or without the Cellectra electroporation delivery device. The HIV Vaccine Trials Network carried out the study. Pennvax-B plus the Cellectra device significantly increased the number of responders giving durable CD4 and CD8 T-cell responses.

• Ohr Pharmaceutical Inc., of New York, enrolled the first 60 patients in an ongoing Phase II trial of squalamine eye drops for wet age-related macular degeneration. The randomized, double-blind, placebo-controlled study will enroll 120 patients at more than 20 clinical sites in the U.S., and will evaluate efficacy and safety of the drops compared to placebo drops over a nine month period.